TRD 1 - Imaging Cancer Heterogeneity

项目摘要 TRD 1：成像癌症异质结 精准医疗是一种范式转变，个性化治疗方法基于对以下方面的了解： 个体的基因型和表现型。虽然重要的是将治疗剂与遗传因子相匹配， 肿瘤的组成，需要新的策略来检测和最佳地表征肿瘤的成像表型。 肿瘤和明确确定肿瘤/无肿瘤边界，以优化患者特异性治疗。因此，在本发明中， 成像在评估肿瘤异质性和准确描述那些需要 决定性的治疗至关重要。利用图像引导精确绘制肿瘤细胞组成， 脑、前列腺和妇科肿瘤负荷的3D映射是表征肿瘤的最佳方法 并在诊断时指导临床管理。 成像癌症异质结TRD的目标是开发和验证分子，微观和 宏观尺度成像技术来表征肿瘤的宏观和微观环境， 肿瘤异质性和肿瘤体积，并改善风险评估，以指导癌症的精确治疗。 虽然最初的研究将集中在脑，前列腺和妇科肿瘤，我们设想的技术 从TRD中得出的发现将广泛适用于各种癌症。因此，目标是 旨在提供肿瘤异质性的新的和详细的映射，并使用质量定义肿瘤边界 光谱成像（MSI）与组织病理学和多参数MRI技术相关。

Project Summary TRD 1: Imaging Cancer Heterogeneity Precision medicine is a paradigm shift whereby personalized treatment approaches are based on knowledge of an individual’s genotype and phenotype. While it is important to match the therapeutic agents to the genetic makeup of a tumor, new strategies are needed to detect and optimally characterize the imaging phenotype of tumors and definitively determine the tumor/no tumor borders to optimize patient-specific treatments. As such, the role of imaging in assessing tumor heterogeneity and accurately characterizing those who will require definitive therapy is critical. Using image guidance for precise mapping of tumor cell composition and accurate 3D mapping of brain, prostate, and gynecological tumor burden is the best approach to characterizing tumors and guiding clinical management at diagnosis. The goal of the Imaging Cancer Heterogeneity TRD is to develop and validate molecular, micro- and macroscale imaging technologies to characterize the macroscopic and microscopic environment of tumors, tumor heterogeneity and tumor volume, and improve risk assessment to guide the precise treatment of cancer. While the initial studies will focus on brain, prostate, and gynecological neoplasms, we envision the technology and findings derived from this TRD will be broadly applicable to a variety of cancers. Hence, the aims are designed to provide novel and detailed mapping of tumor heterogeneity and define tumor borders using mass spectrometry imaging (MSI) correlated with histopathology and multiparametric MRI technologies.